Ea Pharma company information, Employees & Contact Information

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories Yahoo Finance

Newron out-licenses evenamide to Eisai unit EA Pharma The Pharma Letter

Newron stock soars on €117M EA Pharma deal for schizophrenia drug BioWorld MedTech

Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on Fierce Biotech

The top 10 biopharma M&A deals of 2024 Fierce Pharma

Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease: A Prospective Multicenter Study ScienceDirect.com

Newron Pharmaceuticals SpA CHEManager

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS) BioSpace

Eisai Subsidiary inks €117 M deal for schizophrenia treatment in Japan and other Asian territories BioSpectrum Asia

Ensho Therapeutics debuts with IBD assets from Eisai subsidiary FirstWord Pharma

Worldwide License Agreement for EA1080, Oral Selective α4β7 GlobeNewswire

Pathalys Pharma, Inc. Launches with Mission to Address High Priority Needs in Chronic Kidney Disease PR Newswire

THE GASTROINTESTINAL DISEASE BUSINESS OF EISAI CO., LTD. AND 味の素株式会社

MOVICOL® Launched in Japan Eisai

Calypso Biotech Licenses IBD Treatment to EA Pharma drugdiscoverytrends.com

Italy's Newron Pharma flies in Zurich thanks to a drug against schizophrenia Il Sole 24 ORE

EA Pharma continues its international expansion with the acquisition of Groupe W and announces the creation of Olyos Group Industries Cosmétiques

Ensho emerges with inflammatory disease portfolio from Eisai's EA Pharma Fierce Biotech

Ensho debuts to target gut inflammation with oral α4β7 inhibitors BioWorld MedTech

Impact of twice-daily budesonide foam administration on early clinical response and endoscopic remission in patients with ulcerative colitis: a post hoc analysis Wiley Online Library

Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease Yahoo Finance

EA Pharma Enters US And Launches Olyos Group Citeline News & Insights

Lilly, AbbVie, BMS and more rally against UK's 'arbitrary' growth cap on branded drug market Fierce Pharma

Production and Logistics (Demand Chain Systems) Eisai

‘Persistent and severe misconduct’ triggers call for reform of UK drug marketing regulation Fierce Pharma

Real-World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort Study Wiley Online Library

UK pumps £13M into wide-ranging group of manufacturing projects Fierce Pharma

UK lays out strategy to become a top 3 life sciences economy by 2035 Fierce Pharma

Moderna, Novo Nordisk slammed for breaching UK drug marketing code yet again Fierce Pharma

Rejuveron Life Sciences rejuvenates as Centenara Labs Fierce Pharma

Tribunal upholds £130M fine after UK authorities probed 10,000% price hike Fierce Pharma

Accord wins £50M joint investment from UK to bolster local production of cancer, immunology drugs Fierce Pharma

UK's Upperton wraps up £15M manufacturing expansion project Fierce Pharma

5654 sets up life science group to help UK firms reach investors Fierce Pharma

Giiant Pharma raises $11M for drug delivery platform for gastroenterology Drug Delivery Business

Japan launches new treatment for chronic constipation BioSpectrum Asia

HealthCare Royalty Partners signs deal for Japanese market Stamford Advocate

Newron presents H1 2025 results and provides business update Business Wire

Tianjin Tasly in $24 Million Deal for EA Pharma Kidney Disease Drug NAI500

Chronic Idiopathic Constipation Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment DelveInsight | ABBVIE, Eisai Co, Anji Pharma, Yuhan, Renexxion Ireland, Forest Barchart.com

Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset Fierce Biotech

Newron Licenses Evenamide to Myung In Pharm CHEManager

A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill PharmaVoice

AbbVie and Eisai launch auto-injector drug delivery pen Medical Device Network

Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model Nature

Eisai announces agreement to set up new gastrointestinal speciality company Pharmafile

Bayer's blockbuster hopeful Nubeqa, AstraZeneca's Forxiga pick up nods from England's NICE Fierce Pharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster Fierce Biotech

AbbVie and Eisai Announce the Launch of HUMIRA® Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® Eisai

AbbVie joins TL1A race via $150M upfront deal with China's FutureGen Fierce Biotech

Tasly enriches foreign portfolio China Daily - Global Edition

Altamira finds buyer for Zilentin inner ear unit so Swiss biotech can go all-in on RNA Fierce Biotech

Former Liquidia CEO launches new venture targeting kidney disease The Business Journals

Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis ScienceDirect.com

Efficacy of macrogol 4000 plus electrolytes in bowel preparation for colonoscopy in patients with chronic constipation BMC Gastroenterology

Pathalys inks development deal with Abingworth company, raising $150M Endpoints News

Eisai launches bile acid transporter inhibitor Goofice in Thailand BioSpectrum Asia

AbbVie, Eisai launch auto-injector drug delivery pen BioSpectrum Asia

Tasly to Buy Drug Rights to Tackle Kidney Disease in China 一财全球Yicai Global